Development of Drug-Induced Cutaneous Vasculitis in a Patient with Relapsed Angioimmunoblastic T-cell Lymphoma Treated with Novel Bortezomib and Panobinostat Combination: A Possible Surrogate Marker of Response

Yuh Shan Lee1, Leonard Tan2, Choon Chiat Oh3, Yuen Li Ng4, Yeow Tee Goh1 and Daryl Tan1* 1Department of Hematology, Singapore General Hospital, Singapore 2Department of Pathology, Singapore General Hospital, Singapore 3Department of Dermatology, Singapore General Hospital, Singapore 4Department of Radiology, Singapore General Hospital, Singapore Cancer Science & Research: Open Access Open Access Case Report

[1]  A. Gemma,et al.  Bortezomib therapy-related lung disease in Japanese patients with multiple myeloma: Incidence, mortality and clinical characterization , 2014, Cancer science.

[2]  M. Baccarani,et al.  Bortezomib with thalidomide plus dexamethasone compared with thalidomide plus dexamethasone as induction therapy before, and consolidation therapy after, double autologous stem-cell transplantation in newly diagnosed multiple myeloma: a randomised phase 3 study , 2010, The Lancet.

[3]  K. Bhalla,et al.  Phase IA/II Study of Oral Panobinostat (LBH589), a Novel Pan- Deacetylase Inhibitor (DACi) Demonstrating Efficacy in Patients with Advanced Hematologic Malignancies. , 2008 .

[4]  S. Yamasaki,et al.  Stromal cells in bone marrow play important roles in pro-inflammatory cytokine secretion causing fever following bortezomib administration in patients with multiple myeloma , 2008, International journal of hematology.

[5]  P. Atadja,et al.  Histone Deacetylase Inhibitor Panobinostat Induces Clinical Responses with Associated Alterations in Gene Expression Profiles in Cutaneous T-Cell Lymphoma , 2008, Clinical Cancer Research.

[6]  L. Gordon,et al.  Histone Deacetylase Inhibitor (HDACi) PCI-24781 and Bortezomib Result in Synergistic Apoptosis in Hodgkin Lymphoma (HL) and Non-Hodgkin’s Lymphoma (NHL) Cell Lines: Investigation of Cell Death and NFKB-Mediated Pathways. , 2007 .

[7]  K. Anderson,et al.  Aggresome induction by proteasome inhibitor bortezomib and alpha-tubulin hyperacetylation by tubulin deacetylase (TDAC) inhibitor LBH589 are synergistic in myeloma cells. , 2006, Blood.

[8]  D. Esseltine,et al.  Drug‐induced cutaneous vasculitis in patients with non‐Hodgkin lymphoma treated with the novel proteasome inhibitor bortezomib: a possible surrogate marker of response? , 2006, British journal of haematology.

[9]  Yoo-Jin Kim,et al.  Cutaneous leucoclastic vasculitis (LV) following bortezomib therapy in a myeloma patient; association with pro‐inflammatory cytokines , 2006, European journal of haematology.

[10]  Hartmut Goldschmidt,et al.  Bortezomib or high-dose dexamethasone for relapsed multiple myeloma. , 2005, The New England journal of medicine.

[11]  S. Schreiber,et al.  Small-molecule inhibition of proteasome and aggresome function induces synergistic antitumor activity in multiple myeloma. , 2005, Proceedings of the National Academy of Sciences of the United States of America.

[12]  A. Zelenetz,et al.  Phase II clinical experience with the novel proteasome inhibitor bortezomib in patients with indolent non-Hodgkin's lymphoma and mantle cell lymphoma. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[13]  Bart Barlogie,et al.  A phase 2 study of bortezomib in relapsed, refractory myeloma. , 2003, The New England journal of medicine.

[14]  M. Gordon.  Bortezomib plus Melphalan and Prednisone for Initial Treatment of Multiple Myeloma , 2009 .

[15]  P. Sonneveld,et al.  Analysis of the efficacy and toxicity of bortezomib for treatment of relapsed or refractory multiple myeloma in community practice. , 2005, Haematologica.